Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain investors, pre-funded warrants in place of common shares.
All securities in this offering will be issued by Milestone. The offering's completion is subject to market conditions and other factors, with no guarantee regarding its timing, size, or terms.
The proceeds, alongside existing cash reserves, will fund the clinical development and commercial launch of etripamil for paroxysmal supraventricular tachycardia - PSVT, as well as support general corporate activities and working capital.
MIST currently trades at $1.715 or 32.9435% lower on the NasdaqGS.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.